Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease.

Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease.

<h4>Background</h4>Decisions on dual antiplatelet therapy (DAPT) duration should balance the opposing risks of ischaemia and bleeding. Our aim was to develop a risk score to identify stable coronary artery disease (SCAD) patients undergoing PCI who would benefit or suffer from extending...

Full description

Bibliographic Details
Main Authors: Guy Witberg, Ygal Plakht, Tamir Bental, Becca S Feldman, Maya Leventer-Roberts, Amos Levi, Hagit Gabay, Ran Balicer, Yariv Gerber, Ran Kornowski
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0209661

Internet

https://doi.org/10.1371/journal.pone.0209661

Similar Items